Harvard researchers report positive trial results with artificial pancreas smartphone app

New Rochelle, NY, January 25, 2019–The results of a new clinical trial have shown the safety and efficacy of the interoperable Artificial Pancreas System smartphone app (iAPS), which can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms. The clinical trial and the app, which runs on an unlocked smartphone, are described in an article published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Diabetes Technology & Therapeutics (DTT) website through February 25, 2019.

Eyal Dassau, Harvard University (Cambridge, MA), Sansum Diabetes Research Institute (Santa Barbara, CA), and Joslin Diabetes Center (Boston, MA), and colleagues from these institutions and Labrasoft LLC (Leander, TX) coauthored the article entitled “Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development.”

The Artificial Pancreas phase, compared to the Sensor-Augmented Pump phase, trended toward improved time in the target glucose range (70-180 mg/dL) and yielded a statistically significant reduction in time below 70 mg/dL.

“Interoperability is so important with artificial pancreas systems, such that patients and their providers will have a choice for ongoing care of the best CGM and algorithm that fit each patient’s needs. I applaud the researchers evaluating the clinical applications of such systems,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora).

###

Research reported in this publication was supported by the National Institutes of Health under Award Numbers DP3DK104057, DP3DK11351, and R44DK107114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

The Advanced Technologies & Treatments for Diabetes (ATTD) Conference presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.